$BNTX Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of $1.99 down -45.48% YoY
• Reported revenue of $1.49B down -16.21% YoY
• BioNTech raised its FY 2026 revenue guidance midpoint to 17T; adjusted R&D expenses guidance of 20T and adjusted SG&A expenses guidance of 700.8B remain unchanged for the full year.